MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Xencor Inc

Fermé

SecteurSoins de santé

9.28 12.21

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.29

Max

9.29

Chiffres clés

By Trading Economics

Revenu

5.5M

-49M

Ventes

-37M

33M

Marge bénéficiaire

-148.576

Employés

250

EBITDA

-21M

-37M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+225.15% upside

Dividendes

By Dow Jones

Prochains Résultats

1 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-412M

599M

Ouverture précédente

-2.93

Clôture précédente

9.28

Sentiment de l'Actualité

By Acuity

50%

50%

157 / 376 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Xencor Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 juil. 2025, 15:46 UTC

Principaux Mouvements du Marché

BitMine Shares Fall After Closing of $250 Million Private Placement

9 juil. 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 juil. 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 juil. 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 juil. 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 juil. 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9 juil. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

9 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juil. 2025, 20:26 UTC

Résultats

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 juil. 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 juil. 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 juil. 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9 juil. 2025, 17:07 UTC

Market Talk
Acquisitions, Fusions, Rachats

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 juil. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9 juil. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 juil. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

9 juil. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 juil. 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 juil. 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 juil. 2025, 16:14 UTC

Acquisitions, Fusions, Rachats

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 juil. 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 juil. 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 juil. 2025, 15:31 UTC

Principaux Mouvements du Marché

BitMine Shares Fall After Closing of $250M Private Placement

9 juil. 2025, 15:31 UTC

Market Talk
Acquisitions, Fusions, Rachats

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 juil. 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 juil. 2025, 14:36 UTC

Acquisitions, Fusions, Rachats

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 juil. 2025, 14:31 UTC

Acquisitions, Fusions, Rachats

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 juil. 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9 juil. 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Comparaison

Variation de prix

Xencor Inc prévision

Objectif de Prix

By TipRanks

225.15% hausse

Prévisions sur 12 Mois

Moyen 26.89 USD  225.15%

Haut 38 USD

Bas 6 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

10

Achat

0

Maintien

1

Vente

Score Technique

By Trading Central

7.87 / 10.84Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

157 / 376Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.